Analyst Ratings For Nurix Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have recently evaluated Nurix Therapeutics (NASDAQ:NRIX), with 11 analysts providing ratings ranging from bullish to bearish. The average 12-month price target has increased by 13.38% to $29.82. Despite positive analyst sentiment, Nurix faces challenges with a significant revenue decline and negative profitability metrics.
September 04, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Nurix Therapeutics has received positive analyst ratings with an increased average price target of $29.82. However, the company faces significant revenue decline and negative profitability metrics, which may impact investor sentiment.
Analysts have shown optimism with increased price targets, indicating potential upside. However, the company's significant revenue decline and negative profitability metrics may offset this optimism, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100